Recently stock market analysts have updated their consensus ratings on shares of Cleveland BioLabs, Inc. (CBLI). The latest broker reports which are currently outstanding on Monday 9th of May state 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

01/24/2014 – Cleveland BioLabs, Inc. was downgraded to “market perform” by analysts at Oppenheimer. They now have a USD 1.13 price target on the stock.

01/24/2014 – Cleveland BioLabs, Inc. was downgraded to “hold” by analysts at Cantor Fitzgerald. They now have a USD 2 price target on the stock.

Cleveland BioLabs, Inc. has a 50 day moving average of 2.38 and a 200 day moving average of 3.37. The stock’s market capitalization is 22.08M, it has a 52-week low of 1.84 and a 52-week high of 7.24.

The share price of the company (CBLI) was down -0.49% during the last trading session, with a high of 2.06 and the volume of Cleveland BioLabs, Inc. shares traded was 5137.

View other investors thoughts on Cleveland BioLabs, Inc. on our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.